MCID: GLM044
MIFTS: 37

Glomerular Disease

Categories: Nephrological diseases, Rare diseases

Aliases & Classifications for Glomerular Disease

MalaCards integrated aliases for Glomerular Disease:

Name: Glomerular Disease 58 17

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

UMLS via Orphanet 72 C0268731
Orphanet 58 ORPHA93548

Summaries for Glomerular Disease

MalaCards based summary : Glomerular Disease is related to rapidly progressive glomerulonephritis and membranoproliferative glomerulonephritis. An important gene associated with Glomerular Disease is MIR30A (MicroRNA 30a), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Nephrin interactions. The drugs Atorvastatin and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and monocytes, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Glomerular Disease

Diseases related to Glomerular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 rapidly progressive glomerulonephritis 31.5 NPHS1 ALB
2 membranoproliferative glomerulonephritis 31.4 NPHS1 CD79A ALB
3 familial nephrotic syndrome 30.7 NPHS2 NPHS1 CD2AP
4 iga nephropathy 1 30.7 NPHS2 NPHS1 CD79A ACE
5 denys-drash syndrome 30.6 NPHS2 NPHS1 CD2AP
6 focal segmental glomerulosclerosis 1 30.6 NPHS2 NPHS1 CD2AP
7 nephrotic syndrome, type 1 30.6 NPHS2 NPHS1 CD2AP
8 frasier syndrome 30.6 NPHS2 NPHS1 CD2AP
9 microvascular complications of diabetes 3 30.3 NPHS1 ALB ACE
10 genetic steroid-resistant nephrotic syndrome 30.2 NPHS2 NPHS1 CD2AP
11 nephrotic syndrome, type 10 30.2 NPHS2 NPHS1
12 purpura 30.2 CD79A ACE
13 nephrotic syndrome 30.1 NPHS2 NPHS1 CD2AP ALB ACE
14 glomerulonephritis 30.1 NPHS2 NPHS1 CD79A ALB ACE
15 goodpasture syndrome 30.0 NPHS1 ALB
16 henoch-schoenlein purpura 30.0 CD79A ALB
17 chronic graft versus host disease 30.0 CD79A ALB
18 acute poststreptococcal glomerulonephritis 29.9 CD79A ALB
19 diffuse mesangial sclerosis 29.9 NPHS2 NPHS1
20 focal segmental glomerulosclerosis 2 29.8 NPHS2 NPHS1 CD2AP
21 nephrotic syndrome, type 2 29.8 NPHS2 NPHS1
22 lipoid nephrosis 29.7 NPHS2 NPHS1 CD79A CD2AP ALB
23 acute kidney tubular necrosis 29.7 ALB ACE
24 arteriolosclerosis 29.7 CD79A ALB
25 hypertensive nephropathy 29.6 ALB ACE
26 bacteriuria 29.6 CD79A ALB
27 membranous nephropathy 29.6 NPHS2 NPHS1 CD79A CD2AP ALB ACE
28 idiopathic nephrotic syndrome 29.5 NPHS2 ALB ACE
29 interstitial nephritis 29.5 ALB ACE
30 focal segmental glomerulosclerosis 29.5 NPHS2 NPHS1 CD2AP ALB ACE
31 plasma cell neoplasm 29.5 CD79A ALB
32 nail-patella syndrome 29.4 NPHS2 NPHS1 CD2AP
33 acute proliferative glomerulonephritis 29.3 NPHS2 NPHS1 ALB
34 anuria 29.3 ALB ACE
35 nephrosclerosis 29.3 NPHS2 NPHS1 ACE
36 chronic kidney disease 29.3 NPHS2 NPHS1 ALB ACE
37 rheumatic fever 29.2 ALB ACE
38 end stage renal disease 29.1 NPHS2 NPHS1 CD2AP ALB ACE
39 exanthem 29.1 ALB ACE
40 kidney disease 29.1 NPHS2 NPHS1 CD79A CD2AP ALB ACE
41 iga glomerulonephritis 28.7 NPHS2 NPHS1 MIR30A CD79A ALB ACE
42 hypertension, essential 27.6 NPHS2 NPHS1 MIR30A ALB ACE
43 genetic glomerular disease 12.3
44 immunotactoid glomerulopathy 11.6
45 glomerulopathy with fibronectin deposits 2 11.6
46 fibrillary glomerulonephritis 11.6
47 immunotactoid or fibrillary glomerulopathy 11.4
48 loin pain hematuria syndrome 11.2
49 galloway-mowat syndrome 6 11.0
50 nephronophthisis 11.0

Graphical network of the top 20 diseases related to Glomerular Disease:



Diseases related to Glomerular Disease

Symptoms & Phenotypes for Glomerular Disease

MGI Mouse Phenotypes related to Glomerular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 ACE ALB CD2AP CD79A KLF15 NPHS1
2 mortality/aging MP:0010768 9.5 ACE ALB CD2AP CD79A KLF15 NPHS1
3 renal/urinary system MP:0005367 9.17 ACE ALB CD2AP CD79A KLF15 NPHS1

Drugs & Therapeutics for Glomerular Disease

Drugs for Glomerular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Losartan Approved Phase 4 114798-26-4 3961
4
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Uric acid Investigational Phase 4 69-93-2 1175
7 Immunoglobulin A Phase 4
8 Cassava Phase 4
9 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
10 Cyclosporins Phase 4
11 Hypolipidemic Agents Phase 4
12 Anticholesteremic Agents Phase 4
13 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
14 Lipid Regulating Agents Phase 4
15 Calcineurin Inhibitors Phase 4
16 Antihypertensive Agents Phase 4
17 Angiotensin II Type 1 Receptor Blockers Phase 4
18 Angiotensinogen Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Anti-Arrhythmia Agents Phase 4
21 Giapreza Phase 4
22 Sodium Chloride Symporter Inhibitors Phase 4
23 diuretics Phase 4
24
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
25
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
26
Epoprostenol Approved Phase 2, Phase 3 35121-78-9, 61849-14-7 5282411 5280427
27
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
28
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
30
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
31 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
32
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
33
rituximab Approved Phase 3 174722-31-7 10201696
34
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
35
Mycophenolic acid Approved Phase 3 24280-93-1 446541
36
Azathioprine Approved Phase 3 446-86-6 2265
37 Tezosentan Investigational Phase 2, Phase 3 180384-57-0
38 Beraprost Investigational Phase 2, Phase 3 88430-50-6
39
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
40 Dermatologic Agents Phase 3
41 Antifungal Agents Phase 3
42 Vasodilator Agents Phase 2, Phase 3
43 Platelet Aggregation Inhibitors Phase 2, Phase 3
44 Hormones Phase 3
45 Hormone Antagonists Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 glucocorticoids Phase 3
48 Anti-Inflammatory Agents Phase 3
49 Methylprednisolone Acetate Phase 3
50 Protective Agents Phase 3

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
2 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
3 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
4 The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study Completed NCT00768638 Phase 4 Atorvastatin;Atorvastatin
5 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
6 Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: a Randomized, Multicenter, Open-label, Parallel-arm Study Recruiting NCT04048161 Phase 4 Tacrolimus;Mycophenolate Mofetil
7 Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria Suspended NCT00369538 Phase 4 losartan, hydrochlorothiazide;hydrochlorothiazide, losartan
8 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
9 TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT01090037 Phase 2, Phase 3 TRK-100STP high dose;TRK-100STP low dose;Placebo
10 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
11 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Active, not recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
12 A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy. Terminated NCT00504244 Phase 3 switch to Myfortic;continuation of azathioprine
13 A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu) Unknown status NCT01624064 Phase 1, Phase 2 Enalapril;Calcium Supplement
14 TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT02480751 Phase 2 Beraprost;Placebo
15 Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease Active, not recruiting NCT03865407 Phase 2 Allopurinol
16 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Active, not recruiting NCT03970577 Phase 2 Rituximab;Prednisone
17 A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects Completed NCT03719443 Phase 1
18 Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis Completed NCT00275613 Phase 1 Rituximab
19 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Completed NCT01221181 Phase 1 Eculizumab
20 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
21 Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome Unknown status NCT03235128
22 Different Histopathological Patterns in Patients With HCV Nephropathy Unknown status NCT03476031
23 Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy Unknown status NCT00978965
24 Nephrologic Intervention in Patients Waiting for Cardiac Surgery Unknown status NCT02643745
25 Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study. Unknown status NCT01386957
26 Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis Unknown status NCT02811770
27 Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease Completed NCT01835639
28 Histological and Clinical Biomarkers to Predict the Progression of IgA Nephropathy Completed NCT02529722
29 Kidney Disease Biomarkers Completed NCT00255398
30 Lupus Nephritis: Role of Environmental and Occupational Exposures Completed NCT00342329
31 Prospective Evaluation of Albuminuria in HIV Positive Patients Completed NCT00524992
32 Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma. Completed NCT01572857
33 Pathogenesis of Glomerulosclerosis Completed NCT00001392
34 Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00405340 Early Phase 1 Rituximab
35 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
36 Biomarker for Alport Syndrome: An International, Multicenter, Observational, Longitudinal Protocol Recruiting NCT02718027
37 Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population Active, not recruiting NCT02316522
38 Human Urine Sample Collection for Alport Nephropathy Biomarker Studies Terminated NCT01602835

Search NIH Clinical Center for Glomerular Disease

Genetic Tests for Glomerular Disease

Anatomical Context for Glomerular Disease

MalaCards organs/tissues related to Glomerular Disease:

40
Kidney, Endothelial, Monocytes, T Cells, Liver, Neutrophil, Testes

Publications for Glomerular Disease

Articles related to Glomerular Disease:

(show top 50) (show all 2907)
# Title Authors PMID Year
1
Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. 61 46
18776121 2008
2
Urinary ERdj3 and mesencephalic astrocyte-derived neutrophic factor identify endoplasmic reticulum stress in glomerular disease. 61
32203149 2020
3
Hepatitis E: an expanding epidemic with a range of complications. 61
32251845 2020
4
Synergistic impact of pre-diabetes and immunosuppressants on the risk of diabetes mellitus during treatment of glomerulonephritis and renal vasculitis. 61
32541094 2020
5
Mode of initial renal replacement therapy and transplant outcomes in the chronic kidney disease in children (CKiD) study. 61
31797095 2020
6
Bilateral Pulmonary Embolism in a 12-Year-Old Girl with Steroid-Resistant Nephrotic Syndrome. 61
32549197 2020
7
Clinicopathological characteristics and outcome of patients with fibrillary glomerulonephritis: DNAJB9 is a valuable histologic marker. 61
32557205 2020
8
Crk1/2 and CrkL play critical roles in maintaining podocyte morphology and function. 61
32535035 2020
9
microRNA in Extracellular Vesicles Released by Damaged Podocytes Promote Apoptosis of Renal Tubular Epithelial Cells. 61
32517075 2020
10
Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease. 61
31769845 2020
11
Defining renal phenotype in Alström syndrome. 61
30307515 2020
12
Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. 61
32518868 2020
13
Evaluation of serum biomarkers and proteinuria for the early detection of renal damage in dogs with heartworm (Dirofilaria immitis). 61
32512422 2020
14
Parietal epithelial cells role in repair versus scarring after glomerular injury. 61
32235272 2020
15
Outcomes of immunoglobulin-associated mesangiocapillary glomerulonephritis: A South African experience. 61
32463170 2020
16
Application of Delphi method and analytic hierarchy process to establish indicator system for evaluation of rational drug use in children with primary nephrotic syndrome: Observational study. 61
32384442 2020
17
COL4A3 mutation is an independent risk factor for poor prognosis in children with Alport syndrome. 61
32394188 2020
18
Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. 61
32414663 2020
19
Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats. 61
32429914 2020
20
Clinicopathologic and pathologic characteristics of feline proteinuric kidney disease. 61
32456516 2020
21
Histologic Case Definition of an Atypical Glomerular Immune-Complex Deposition Following Kidney Transplantation. 61
32405585 2020
22
Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. 61
32354728 2020
23
Low Serum Bicarbonate and CKD Progression in Children. 61
32467307 2020
24
The importance of clinician, patient and researcher collaborations in Alport syndrome. 61
31044288 2020
25
Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. 61
32439965 2020
26
Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. 61
32444394 2020
27
The Spectrum of Glomerular Diseases in Mashhad According to Kidney Biopsy Records. 61
32361694 2020
28
B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease. 61
32479988 2020
29
Glomerulonephritis Histopathological Pattern Change. 61
32423387 2020
30
IgA nephropathy in children and in adults: two separate entities or the same disease? 61
32314305 2020
31
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy. 61
32354727 2020
32
The zinc fingers and homeoboxes 2 protein ZHX2 and its interacting proteins regulate upstream pathways in podocyte diseases. 61
32059999 2020
33
Collagenofibrotic glomerulopathy- report of a rare renal disease with serial biopsies. 61
32342943 2020
34
Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin Misclassified as Focal Segmental Glomerulosclerosis or Hereditary Glomerular Disease. 61
32274456 2020
35
Proteinuria-take a closer look! 61
31925536 2020
36
Renal histopathology spectrum in children with kidney diseases in Saudi Arabia, 1998-2017. 61
32291423 2020
37
Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. 61
30852663 2020
38
Mercury in natural health products as a cause of membranous nephropathy. 61
32313474 2020
39
Alport's Syndrome: A Rare Clinical Presentation with Crescents. 61
32269440 2020
40
Identification of differentially expressed circulating exosomal lncRNAs in IgA nephropathy patients. 61
32234013 2020
41
Podocyte infolding glomerulopathy with undifferentiated connective tissue disease: a case report. 61
32172632 2020
42
Proteome Analysis of Isolated Podocytes Reveals Stress Responses in Glomerular Sclerosis. 61
32047005 2020
43
Renal involvement in IgG4-related disease. 61
32234380 2020
44
Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling. 61
31924670 2020
45
Genetic Disorders of the Glomerular Filtration Barrier. 61
32205319 2020
46
Patterns in renal diseases diagnosed by kidney biopsy: A single-center experience. 61
31955562 2020
47
Socioeconomic Position and Incidence of Glomerular Diseases. 61
32079609 2020
48
Association of Time-Varying Blood Pressure With Chronic Kidney Disease Progression in Children. 61
32058554 2020
49
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. 61
31119846 2020
50
Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views. 61
31847609 2020

Variations for Glomerular Disease

Expression for Glomerular Disease

Search GEO for disease gene expression data for Glomerular Disease.

Pathways for Glomerular Disease

Pathways related to Glomerular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11 NPHS2 NPHS1 CD2AP
2 10.5 NPHS1 CD2AP
3 10.21 NPHS2 NPHS1 CD2AP

GO Terms for Glomerular Disease

Cellular components related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 slit diaphragm GO:0036057 8.62 NPHS2 NPHS1

Biological processes related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 8.62 NPHS2 NPHS1

Sources for Glomerular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....